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Introduction 
Chronic lung infections from the opportunistic pathogeen Pseudomonas aeruginosa 
has been recognised as a major contributor to the incidences of high morbidity and 
mortality amongst cystic fibrosis (CF) patients (1,2). Currently, strategies for 
managing lung infections in CF patients involves the aggressive use of aerosolised 
antibiotics (3), however, increasing evidence suggests that the biofilm component of 
P. aeruginosa in the lower airway remains unperturbed and is associated with the 
development of antibiotic resistance. If this is so then, there is an urgent need to 
suitably adjust the current treatment strategy so that it includes compounds that 
prevent biofilm formation or disrupt established biofilms.  
It is well understood that biofilm formation is strongly dependent on iron (Fe3+) 
availability (4), therefore aerosolised anti-infective formulations which has the ability 
to chelate iron may essentially be a well suited therapy for eliminating P. aeruginosa 
biofilms on CF airway epithelial cells (5). 
In this study, we report the use of combination therapy; an aminoglycosides 
(tobramycin and gentamicin) and an antimicrobial peptide (lactoferrin) to significantly 
deplete P. aeruginosa biofilms. We demonstrate that lactoferrin-tobramycin and 
lactoferrin-gentamicin combinations are superior to the single antibiotic regime 
currently being employed to combat P. aeruginosa biofilms. 
 
MATERIALS AND METHOD 
Antibiotics: The antibiotics used in this study included gentamicin and tobramycin 
supplied by Fagron, UK. 
Bacterial strain and growth conditions: Pseudomonas aeruginosa strain PAO1 was 
provided by Prof. Peter Lambert of Aston University, Birmingham UK.  The Strains 
were routinely grown from storage in a medium supplemented with magnesium 
chloride, glucose and casamino acids. 
Dialysis of lactoferrin: Apo lactoferrin was prepared by dialyzing a suspension of 
lactoferrin for 24 hrs at 4 °C against 20 mmol/L sodium dihydrogen phosphate, 20 
mmol/L sodium acetate and 40 mmol/L EDTA (pH 3.5). Ferric ion (Fe3+) removal was 
verified by atomic absorption spectroscopy measurements. 
Spray drying of combinations of lactoferrin and apo lactoferrin with the different 
aminoglycosides: Combinations of tobramycin and gentamicin with the different 
preparations of lactoferrin were spray dried (SD) as a 2% (w/v) aqueous suspension. 
The spray drying parameters utilized for the production of suitable micron-sized 
particles includes: Inlet temperature, 180°C, spray flow rate, 606 L/hr; pump setting, 
10%; aspirator setting, 85% (34m3/hr) to produce various outlet temperatures 
ranging from 99 - 106°C. 
Viability assay: To test the bactericidal activity of the various combinations, a viability 
assay was performed as previously described by Xu, Xiong et al. (6) with some 
modifications. Briefly, 10µL of ~ c. 6.6 x 107 CFU mL-1 P. aeruginosa strain PAO1 
suspension were incubated (37°C, 60 mins) with 90 µL of a 2 µg/mL concentration of 
the various combinations and sampled every 10 mins. After incubation, the cells 
were diluted in deionised water and plated in Mueller hinton agar plates. Following 
24 h incubation of the plates at 37°C, the percentage of viable cells was determined 
relative to incubation without added antibiotics. 
Biofilm assay: To test the susceptibility of the P. aeruginosa strain to various 
antibiotics in the biofilms mode of growth, overnight cultures of P. aeruginosa were 
diluted 1:100 into fresh medium supplemented with magnesium chloride, glucose 
and casamino acids. Aliquots of the dilution were dispensed into a 96 well dish and 
incubated (37°C, 24 h). Excess broth was removed and the number of colony 
forming units per milliliter (CFU/mL) of the planktonic bacteria was quantified. The 
biofilms were then washed and stained with 0.1% (w/v) crystal violet for 15 mins at 
room temperature. Following vigorous washing with water, the stained biofilms were 
solubilized in 30% acetic acid and the absorbance at 550nm of a 125 µL aliquot was 
determined in a microplate reader (Multiskan spectrum, Thermo Scientific) using 
30% acetic acid in water as the blank. Aliquots of the broth prior to staining were 
used as an indicator of the level of planktonic growth. 
 
RESULTS AND DISCUSSION 
Following spray drying, the mean yield, volume weighted mean diameter and 
moisture content of lactoferrin powder were measured and were as follows (Table 1 
and table 2); 
 
Table 1: Spray drying parameters 
Formulation Inlet 
temp 
(°C) 
Outlet 
temp 
(°C) 
Airflow 
rate 
(L/hr) 
Mean 
yield (%) 
Moisture 
content 
(%) 
SD Lactoferrin 180 99 - 100 606 45.2 ±2.7 5.9 ±0.4 
SD Apo Lactoferrin 180 100 - 102 606 57.8 ±1.8 5.7 ±0.2 
Tobramycin 180 102 - 104 606 82.1 ±2.2 3.2 ±0.4 
Lactoferrin + Tobramycin 180 104 - 106 606 87.5 ±1.4 3.7 ±0.2 
Apo Lactoferrin + Tobramycin 180 103 - 104 606 76.3 ±2.4 3.3 ±0.5 
Gentamicin 180 99 - 102 606 85.4 ±1.3 4.0 ±0.2 
Lactoferrin + Gentamicin 180 102 - 104 606 87.3 ±2.1 3.9 ±0.3 
Apo Lactoferrin + Gentamicin 180 99 -103 606 80.1±1.9 3.4 ±0.4 
 
 Table 2: Particle size distribution 
 d10  d50 d90 
SD Lactoferrin 1.38 4.91 11.08 
SD Apo Lactoferrin 1.28 4.79 11.04 
SD Tobramycin 1.25 4.90 11.29 
SD Lactoferrin + Tobramycin 1.17 5.27 15.23 
SD Apo Lactoferrin + Tobramycin 1.11 5.06 14.31 
SD Gentamicin 1.40 6.06 14.38 
SD Lactoferrin + Gentamicin 1.47 6.23 14.41 
SD Apo Lactoferrin + Gentamicin 1.46 5.15 11.53 
 
The bactericidal activity of the various combinations were tested against P. 
aeruginosa PAO1 following a 60 minute incubation period (Figure 1 and Figure 2). 
While 2 µg/mL of a 1:1 combination of spray dried apo lactoferrin and Gentamicin 
was able to completely kill all bacterial cells within 40 mins, the same concentration 
was not as effective for the other antibiotic combinations. However, there was an 
overall  reduction of bacterial cells by over 3 log units by the other combinations 
within 60 mins. 
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Figure 1: Logarithmic plot of bacterial cell viability of various combinations of 
tobramycin and lactoferrin preparations at 2µg/mL (n = 3). 
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Figure 2: Logarithmic plot of bacterial cell viability of various combinations of 
gentamicin and lactoferrin preparations at 2µg/mL (n = 3). 
 
Crystal violet staining showed that biofilm formation by P. aeruginosa PAO1 was 
significantly (ANOVA, p < 0.05) inhibited in the presence of the different lactoferrin 
preparations. Interestingly, apo lactoferrin and spray dried lactoferrin exhibited 
greater inhibition of both biofilm formation and biofilm persistence (Figure 2). 
 
 
 Figure 2: Crystal violet staining of residual biofilms of P. aeruginosa following a 24hr 
incubation with the various combinations of antibiotics and an exposure to 48 hr 
formed biofilms. 
 
CONCLUSION 
In conclusion, combination therapy comprising of an antimicrobial peptide 
(lactoferrin) and an aminoglycosides (tobramycin or gentamicin) provides a feasible 
and alternative approach to monotherapy since the various combinations are more 
efficient than the respective monotherapy in the eradication of both planktonic and 
biofilms of P. aeruginosa.  
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